Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breast Cancer Predisposition Genes and Synthetic Lethality.

International journal of molecular sciences - 25 May 2021

Neiger Hannah E, Siegler Emily L, Shi Yihui

Abstract excerpt

BRCA1 and BRCA2 are tumor suppressor genes with pivotal roles in the development of breast and ovarian cancers. These genes are essential for DNA double-strand break repair via homologous recombination (HR), which is a virtually error-free DNA repair mechanism. Following BRCA1 or BRCA2 mutations, HR is compromised, forcing cells to adopt alternative error-prone repair pathways that often result in tumorigenesis....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair

Share to Fanconi Anemia Complementation Group N Protein

Share to Genetic Predisposition to Disease

Share to PARP inhibition in cancer therapy

Share to Synthetic Lethal Mutations

Source

Open in PubMed Open full text

Identifiers

PMID: 34070674
DOI: 10.3390/ijms22115614
PMCID: PMC8198377

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breast Cancer Predisposition Genes and Synthetic Lethality.PMID 34070674Read ↗

BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.Semantic proximity Read ↗

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedsideSemantic proximity Read ↗

Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer.Semantic proximity Read ↗

Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2Semantic proximity Read ↗

BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethalitySemantic proximity Read ↗

Synthetic lethality: exploiting the addiction of cancer to DNA repair.Semantic proximity Read ↗

Crosstalk of DNA double‐strand break repair pathways in poly(ADP‐ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2‐mutated cancerSemantic proximity Read ↗

BRCA in breast cancer: from risk assessment to therapeutic prediction.Semantic proximity Read ↗

Harnessing DNA Double-Strand Break Repair for Cancer TreatmentSemantic proximity Read ↗

Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements.Semantic proximity Read ↗

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.Semantic proximity Read ↗

Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.